<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03191513</url>
  </required_header>
  <id_info>
    <org_study_id>HR-16/17-4397</org_study_id>
    <nct_id>NCT03191513</nct_id>
  </id_info>
  <brief_title>The Acute Effects of Interesterification of Commercially Used Fats on Postprandial Fat Metabolism</brief_title>
  <acronym>INTERMET</acronym>
  <official_title>The Acute Effects of Interesterification of Commercially Used Fats on Postprandial Fat Metabolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>King's College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>King's College London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate whether there are differences in postprandial
      metabolic indices following interesterified fats used commercially versus the corresponding
      un-interesterified blend.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aim: The current study aims to investigate the acute effects of commercially relevant
      interesterified 'hardstock' versus the corresponding un-interesterified blend on 8 h
      postprandial fat metabolism.

      Hypothesis: Interesterification of a palm kernel and palm stearin fat blend, to produce a fat
      with a higher proportion of palmitic acid in the middle position of the triglyceride (TAG;
      but the same fatty acid composition), will alter postprandial lipid metabolism.

      Subjects: Participants will include 24 healthy male and female (postmenopausal) volunteers
      aged between the ages of 45 and 75 years (since during this age metabolic changes start to
      take place).

      Power calculation: Based on previous studies carried out by our group at King's College
      London, a sample size of 12 males and 12 females to detect a (clinically relevant) difference
      (for males and females separately) between means of 0.3 mmol/L maximal difference in 8 h
      plasma TAG concentration (standard deviation 0.33 mmol/L, significance level (alpha) of 0.05
      and 80% power). This will allow for a 20% drop out rate.

      Expected value:The study will provide novel information on the acute effects of commercially
      relevant processed fats on postprandial lipaemia.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 12, 2017</start_date>
  <completion_date type="Anticipated">February 27, 2018</completion_date>
  <primary_completion_date type="Anticipated">October 15, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under plasma TAG concentration/ time curve</measure>
    <time_frame>Up to 8 hours</time_frame>
    <description>Postprandial area under plasma TAG concentration/ time curve</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postprandial lipaemic response</measure>
    <time_frame>Up to 8 hours</time_frame>
    <description>Postprandial plamsa total fatty acid composition and non esterifed fatty acid</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positional composition retention (chylomicron)</measure>
    <time_frame>Up to 6 hours</time_frame>
    <description>Postprandial chylomicron TAG concentration and composition, TAG sn-2 fatty acid composition, total protein, apoB100 and apoB48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atherogenic potential (lipoprotein)</measure>
    <time_frame>Up to 8 hours</time_frame>
    <description>Postprandial lipoprotein size (LDL, VLDL and HDL) and composition (total and small LDL, large VLDL and total and large HDL)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>2 and 3 MCPD and glycidyl esters</measure>
    <time_frame>Up to 8 hours</time_frame>
    <description>Postprandial plasma 2 and 3-monochloropropane-1,2-diol or 3-chloropropane-1,2-diol glycidyl esters</description>
  </other_outcome>
  <other_outcome>
    <measure>Isotope lablelled parameters</measure>
    <time_frame>Up to 8 hours</time_frame>
    <description>In sub-group, n=12, postprandial 13C TAG concentration and breath CO2 13C</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Healthy Adults</condition>
  <condition>Postmenopausal Women</condition>
  <arm_group>
    <arm_group_label>Interesterified</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Interesterified blend of palm kernal and plam stearin. 50g fat.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Un-interesterified</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Un-interesterified blend of palm kernal and plam stearin. 50g fat.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rapeseed oil. 50g fat.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Interesterified blend of palm kernal and plam stearin</intervention_name>
    <description>50 g fat provided as interesterified palm kernal and palm sterin blend in a single meal (sub-group, n=12, also have 75 mg 13C labelled tripalmatin and 1.2 g / kg body water deuterated water)</description>
    <arm_group_label>Interesterified</arm_group_label>
    <other_name>Interesterified blend</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Un-interesterified blend of palm kernal and plam stearin</intervention_name>
    <description>50 g fat provided as un-interesterified palm kernal and palm sterin blend in a single meal (sub-group, n=12, also have 75 mg 13C labelled tripalmatin and 1.2 g / kg body water deuterated water)</description>
    <arm_group_label>Un-interesterified</arm_group_label>
    <other_name>Un-interesterified blend</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Rapeseed oil</intervention_name>
    <description>50 g fat provided as rapeseed oil in a single meal (sub-group, n=12, also have 75 mg 13C labelled tripalmatin and 1.2 g / kg body water deuterated water)</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>Control fat</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females aged 45-75 years

          -  Postmenopausal (for women)

          -  Healthy (free of diagnosed diseases listed in exclusion criteria)

          -  Able to understand the information sheet and willing to comply with study protocol

          -  Able to give informed consent

        Exclusion Criteria:

          -  Medical history of myocardial infarction, angina, thrombosis, stroke, cancer, liver or
             bowel disease or diabetes

          -  Body mass index &lt; 20 kg/m2 or &gt; 35 kg/m2

          -  Plasma cholesterol ≥7.5 mmol/L

          -  Plasma triacylglycerol &gt; 3 mmol/L

          -  Plasma glucose &gt; 7 mmol/L

          -  Blood pressure ≥140/90 mmHg

          -  Current use of antihypertensive or lipid lowering medications

          -  Premenopausal (for women)

          -  Alcohol intake exceeding a moderate intake (&gt; 28 units per week)

          -  Current cigarette smoker (or quit withint the last 6 months)

          -  ≥ 20% 10-year risk of CVD as calculated using a risk calculator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sarah EE Berry, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>King's College London</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sarah EE Berry, PhD</last_name>
    <phone>0207 848 4088</phone>
    <phone_ext>4088</phone_ext>
    <email>sarah.e.berry@kcl.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Charlotte E Mills, PhD</last_name>
    <phone>0207 848 4345</phone>
    <phone_ext>4345</phone_ext>
    <email>charlotte.1.mills@kcl.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>King's College London</name>
      <address>
        <city>London</city>
        <zip>SE1 9NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charlotte E Mills, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 23, 2017</study_first_submitted>
  <study_first_submitted_qc>June 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2017</study_first_posted>
  <last_update_submitted>June 14, 2017</last_update_submitted>
  <last_update_submitted_qc>June 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Interesterified</keyword>
  <keyword>Postprandial</keyword>
  <keyword>Lipid</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

